Literature DB >> 22310095

Repeat surgical interventions following "definitive" instrumentation and fusion for idiopathic scoliosis: five-year update on a previously published cohort.

Brandon A Ramo1, B Stephens Richards.   

Abstract

STUDY
DESIGN: A retrospective case series.
OBJECTIVE: To identify the overall reoperation rate and factors contributing to reoperation in a recent 5-year cohort of patients (2003-2007) undergoing spinal deformity surgery. These patients were compared with a previously published 15-year cohort of consecutive patients (1988-2002) from the same institution to assess for any significant differences in reoperation rates. SUMMARY OF BACKGROUND DATA: In a previously published report from this institution, the reoperation rate for patients with idiopathic scoliosis treated during a 15-year period (1988-2002) was 12.9%. That group was predominantly treated with first-generation TSRH (Medtronic, Memphis, TN) implants and CD implants. Lower profile, more rigid implant systems are now used along with refined techniques for correction of scoliosis deformity. We hypothesized that these factors would lead to lower rates of reoperation. METHODS.: The medical records of 452 consecutive patients (older than 9 yr) surgically treated for idiopathic scoliosis at one institution during 5 years (2003-2007) were reviewed to identify those who required reoperation.
RESULTS: The reoperation rate for this cohort was 7.5% (34 of 452 patients). Compared with the prior cohort, significant decreases were noted with regard to total reoperation rate as well as reoperation due to infection and pseudarthrosis. Trends were noted toward decreased rates of reoperation due to prominent implants, dislodged implants, and implant proximity to vital structures. Within the newer cohort, a trend toward decreased reoperation rate was also noted for lower profile implant systems compared with first-generation TSRH implants.
CONCLUSION: With the evolution of newer lower profile segmental implant systems that provide more rigid fixation and with the advancements in techniques for deformity correction, the repeat surgical intervention rate for idiopathic scoliosis has decreased.

Entities:  

Mesh:

Year:  2012        PMID: 22310095     DOI: 10.1097/BRS.0b013e31824b6b05

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  6 in total

1.  Comparing short-term AIS post-operative complications between ACS-NSQIP and a surgeon study group.

Authors:  Jennifer M Bauer; Suken A Shah; Paul D Sponseller; Amer F Samdani; Peter O Newton; Michelle C Marks; Baron S Lonner; Burt Yaszay
Journal:  Spine Deform       Date:  2020-07-27

2.  Risk of revision surgery for adult idiopathic scoliosis: a survival analysis of 517 cases over 25 years.

Authors:  Guillaume Riouallon; Benjamin Bouyer; Stéphane Wolff
Journal:  Eur Spine J       Date:  2016-03-10       Impact factor: 3.134

3.  Impact of Increasing Age on Outcomes of Spinal Fusion in Adult Idiopathic Scoliosis.

Authors:  Terence Verla; Owoicho Adogwa; Ulysses Toche; S Harrison Farber; Frank Petraglia; Kelly R Murphy; Steven Thomas; Parastou Fatemi; Oren Gottfried; Carlos A Bagley; Shivanand P Lad
Journal:  World Neurosurg       Date:  2015-11-04       Impact factor: 2.104

4.  Unplanned reoperation within 30 days of fusion surgery for spinal deformity.

Authors:  Zheng Li; Jianxiong Shen; Guixing Qiu; Haiquan Yu; Yipeng Wang; Jianguo Zhang; Hong Zhao; Yu Zhao; Shugang Li; Xisheng Weng; Jinqian Liang; Lijuan Zhao
Journal:  PLoS One       Date:  2014-03-04       Impact factor: 3.240

Review 5.  Incidence and risk factors of reoperation in patients with adjacent segment disease: A meta-analysis.

Authors:  Major B Burch; Nicholas W Wiegers; Sonal Patil; Ali Nourbakhsh
Journal:  J Craniovertebr Junction Spine       Date:  2020-04-04

6.  Data-driven Classification of the 3D Spinal Curve in Adolescent Idiopathic Scoliosis with an Applications in Surgical Outcome Prediction.

Authors:  Saba Pasha; John Flynn
Journal:  Sci Rep       Date:  2018-11-02       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.